SURF News and Press, Surface Oncology Inc. From 06/20/23

2023-06-20 13:09:06 ET This will likely be another active week for traders. Whether you’re trading penny stocks or higher priced shares of companies like Tesla ( NASDAQ: TSLA ) and Apple ( NASDAQ: AAPL ), chances are you’re paying attention to stock market news hea...

2023-06-20 12:52:10 ET Summary A lot has been happening with Coherus Biosciences since my last note in January. Coherus is set to acquire Surface Oncology, adding 2 drugs to its immuno-oncology portfolio that could work in combo with PD-1 inhibitor Topripalimab. Toripalimab is...

NEW YORK, NY / ACCESSWIRE / June 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Eneti Inc. (NYSE:NETI)'s sale to Ca...

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ ...

2023-05-04 09:39:12 ET Surface Oncology press release ( NASDAQ: SURF ): Q1 GAAP EPS of -$0.33 beats by $0.04 . As of March 31, 2023, cash, cash equivalents and marketable securities were $102.1 million, compared to $124.8 million on December 31, 2022. ...

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface...

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti...

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF...

2023-03-09 07:16:34 ET Surface Oncology press release ( NASDAQ: SURF ): Q4 GAAP EPS of -$0.35 misses by $0.03 . As of December 31, 2022, cash, cash equivalents and marketable securities were $124.8 million, compared to $154.1 million on December 31, 2021. ...

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into th...